Significant Correction of Disease After Postnatal Administration of Recombinant Ectodysplasin A in Canine X-Linked Ectodermal Dysplasia

In the 2007 study, researchers found that postnatal administration of recombinant ectodysplasin A (Fc:EDA1) to dogs with X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) resulted in significant improvements in symptoms of the disease. The treatment was particularly effective in developing a more complete and anatomically correct adult dentition, improving mucociliary clearance, enhancing lacrimation to near wild-type levels, and enabling the ability to sweat. However, it did not affect hair growth. The study involved 9 dogs in total, with 3 receiving a single injection, 1 receiving four injections, and 5 receiving five higher doses under the T5x2 protocol. The findings suggest that such treatment could be beneficial for human patients with XLHED, although the timing of treatment is crucial due to differences in developmental stages between dogs and humans.